BioCentury
ARTICLE | Clinical News

Cynapsus reports early Phase III data for PD candidate

July 19, 2016 7:00 AM UTC

Cynapsus Therapeutics Inc. (TSX:CTH; NASDAQ:CYNA) reported data from the open-label, dose-escalation portion of the Phase III CTH-300 study evaluating APL-130277 to treat "off" episodes in patients with Parkinson's disease (PD).

In 92 evaluable PD patients, the company said the mean change on the Movement Disorder Society's Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS Part III) score from baseline to 30 minutes after dosing was 22 points. Cynapsus said improvement in motor function was maintained, with a mean MDS-UPDRS Part III change of 16 points at 90 minutes. ...